We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go: Extended investment: Withheld
JOHNNY'S is an ethical, vegan, and sex-positive subscription condom brand. The company aims to deliver its products on a subscription basis, following in the footsteps of Direct-To-Consumer (DTC) health disruptors like Harry's and Dollar Shave Club. It aims to become a contender in the global condom market that is set to be worth $15 Billion by 2026 and enter the lubricant and sex toy market later in 2021. The company has also pledged to give a condom to HIV/STI/NHS clinics for each condom sold. It will use the investment for a PR launch, social media advertising, stock purchase, and attract talent to help the business hit its growth targets.
days to go: Expired investment: £182,281
GreenPiP produce sustainably sourced, green packaging for the packaging market. Their packaging will be made of just one material and therefore it is easier for the agencies that deal with recycling once it has been discarded.
days to go: Expired investment: £105,000
Biohm is an eco-conscious bio-technology company that is revolutionising construction through nature-inspired innovation. The company has adopted methods such as circular construction system, biomimicry, and triagomy. Some of the company’s carbon-negative bio-based materials include building insulation made out of Mycelium (the root structure of mushrooms) and ORB (Organic Refuse Biocompound), a 100% natural sheet material made out of food and agricultural surplus. For its innovation, Biohm won the Waitrose and Partners Plan Plastic Prize: The Million Pound Challenge and a Power to Change grant worth £600,000 to build sustainable living premises. It has also been shortlisted as one of The United Nation’s ‘Young Champions of the Earth’. The company will use 38% of the investment to grow its team, 22% to scale Research and Development (R&D), 22% to protect its Intellectual Property (IP), and 18% for product accreditation.

Pitch Rated

83%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £790,700
Medics2You's is a hybrid telehealth platform that connects patients with healthcare experts around the globe with focus on Africa through a smart device from anywhere, six days a week. The company has a pilot project underway in Nigeria, a nation which spends $500m-1bn annually on outbound healthcare tourism. Medics2You aims to reach out to over 100m people unable to access quality healthcare. Medics2You's partnership with Lantum has given the company access to 18000+ doctors and 3000 clinicians. The funds will be used to create the web portal, expand the team, set up local centres, and enhance marketing activities.

Pitch Rated

76%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £156,370
Ingle & Rhode has come up with ethical and traceable wedding bands and rings. The company has sold more than 6,000 rings directly to the customers. It has achieved a rating of 5-star on Trustpilot and became a finalist of 2015, 2016 and 2017 UK Jewellery Awards. They aim to offer an exceptional combination of premium quality and ethical credentials. With the proceeds, the company will boost its digital marketing campaign.

Pitch Rated

71%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £118,080
Quinola Mothergrain is a plant protein company that aims to disrupt the £3bn rice industry. It offers products that are aimed at boosting the economy and community development to a sustainably beneficial future. The company has received FDA approval in the US, and it has been listed in Ocado and Holland & Barret. It has won many awards including Best Organic Toddler Range (Loved by Parents Awards). The company will use the funds for improving revenues.
days to go: Expired investment: £330,795
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph